BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer
pharmafile | October 23, 2019 | News story | Research and Development | Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that the drug, when combined with Yervoy (ipilimumab) and two cycles of chemotherapy, met its primary endpoint for the first-line treatment of advanced non-small cell lung cancer (NSCLC).
At a pre-specified analysis, the results illustrated that the combo showed superior overall survival benefit in relation to its comparator, chemotherapy monotherapy for up to four cycles followed by optional maintenance therapy.
The safety profile for the combo therapy was also found to be “reflective” of the existing data on its constituent immunotherapy and chemotherapy components in first-line NSCLC.
“We are excited by the CheckMate -9LA results, which demonstrate the potential of Opdivo plus low-dose Yervoy to provide a survival benefit to patients with NSCLC in the first-line setting when administered concomitantly with a limited course of chemotherapy,” said Dr Fouad Namouni, Head of Oncology Development at BMS. “These results build on the benefit the combination of Opdivo plus Yervoy has previously shown in first-line melanoma, renal cell carcinoma and most recently lung cancer, and may provide a new therapeutic option for patients.”
The company confirmed that it plans to present the full results of the trial at an upcoming medical congress and will be also be submitting them to global regulatory authorities.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
